Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2008-1-3
pubmed:abstractText
The receptor for atrial natriuretic peptide (ANP), natriuretic peptide receptor A (NPRA), is expressed in cancer cells, and natriuretic peptides have been implicated in cancers. However, the direct role of NPRA signaling in tumorigenesis remains elusive. Here, we report that NPRA expression and signaling is important for tumor growth. NPRA-deficient mice showed significantly reduced antigen-induced pulmonary inflammation. NPRA deficiency also substantially protected C57BL/6 mice from lung, skin, and ovarian cancers. Furthermore, a nanoparticle-formulated interfering RNA for NPRA attenuated B16 melanoma tumors in mice. Ectopic expression of a plasmid encoding NP73-102, the NH(2)-terminal peptide of the ANP prohormone, which down-regulates NPRA expression, also suppressed lung metastasis of A549 cells in nude mice and tumorigenesis of Line 1 cells in immunocompetent BALB/c mice. The antitumor activity of NP73-102 was in part attributed to apoptosis of tumor cells. Western blot and immunohistochemistry staining indicated that the transcription factor, nuclear factor-kappaB, was inactivated, whereas the level of tumor suppressor retinoblastoma protein was up-regulated in the lungs of NPRA-deficient mice. Furthermore, expression of vascular endothelial growth factor was down-regulated in the lungs of NPRA-deficient mice compared with that in wild-type mice. These results suggest that NPRA is involved in tumor angiogenesis and represents a new target for cancer therapy.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1538-7445
pubmed:author
pubmed:issnType
Electronic
pubmed:day
1
pubmed:volume
68
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
249-56
pubmed:meshHeading
pubmed-meshheading:18172317-Adenocarcinoma, pubmed-meshheading:18172317-Animals, pubmed-meshheading:18172317-Apoptosis, pubmed-meshheading:18172317-Cell Transformation, Neoplastic, pubmed-meshheading:18172317-Female, pubmed-meshheading:18172317-Guanylate Cyclase, pubmed-meshheading:18172317-Inflammation, pubmed-meshheading:18172317-Lung Neoplasms, pubmed-meshheading:18172317-Mice, pubmed-meshheading:18172317-Mice, Knockout, pubmed-meshheading:18172317-Mice, Mutant Strains, pubmed-meshheading:18172317-NF-kappa B, pubmed-meshheading:18172317-Nanoparticles, pubmed-meshheading:18172317-Neoplasms, pubmed-meshheading:18172317-Neovascularization, Pathologic, pubmed-meshheading:18172317-Ovarian Neoplasms, pubmed-meshheading:18172317-RNA, Small Interfering, pubmed-meshheading:18172317-RNA Interference, pubmed-meshheading:18172317-Receptors, Atrial Natriuretic Factor, pubmed-meshheading:18172317-Retinoblastoma Protein, pubmed-meshheading:18172317-Skin Neoplasms, pubmed-meshheading:18172317-Vascular Endothelial Growth Factor A
pubmed:year
2008
pubmed:articleTitle
Natriuretic peptide receptor a as a novel anticancer target.
pubmed:affiliation
Joy McCann Culverhouse Airway Disease and Nanomedicine Research Center, Allergy and Immunology Division, Department of Internal Medicine, University of South Florida College of Medicine, Tampa, FL 33612, USA.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural